|
Published by: Global Markets Direct
Published: Dec. 8, 2010 - 148 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Alzheimer's Disease Overview
- An Overview of Pipeline Products for Alzheimer's Disease
- Alzheimer's Disease Therapeutics under Development by Companies
- Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Companies Involved in Alzheimer's Disease Therapeutics Development
- Bristol-Myers Squibb Company
- DURECT Corporation
- Johnson & Johnson
- Boehringer Ingelheim GmbH
- Abbott Laboratories
- NsGene A/S
- Sanofi-Aventis
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline plc
- Antigenics, Inc.
- Daiichi Sankyo Company, Ltd
- Merck & Co., Inc.
- United Biomedical, Inc.
- Dainippon Sumitomo Pharma Co., Ltd.
- Myriad Genetics, Inc.
- Takeda Pharmaceutical Company Limited
- ExonHit Therapeutics SA
- Plexxikon Inc.
- Mochida Pharmaceutical Co., Ltd.
- Avineuro Pharmaceuticals, Inc.
- Senexis Limited
- Novartis AG
- EnVivo Pharmaceuticals
- DECODON GmbH
- Astellas Pharma Inc.
- Cephalon, Inc.
- Chiesi Farmaceutici SpA
- Daewoong Pharmaceutical Co., Ltd.
- Elan Corporation, plc
- H Lundbeck A/S
- Octapharma AG
- Orion Corporation
- Pfizer Inc.
- Sunesis Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Limited
- Toyama Chemical Co. Ltd
- ENKAM Pharmaceuticals A/S
- Astex Therapeutics Limited
- Addex Pharmaceuticals
- Evotec Aktiengesellschaft
- Anavex Life Sciences Corp.
- Amicus Therapeutics, Inc.
- Genfit
- Idera Pharmaceuticals, Inc.
- Ligand Pharmaceuticals Incorporated
- BELLUS Health Inc
- Medivir AB
- ReGenX Biosciences, LLC
- Neuren Pharmaceuticals Limited
- Neuro-Hitech, Inc.
- Cortex Pharmaceuticals, Inc.
- Critical Outcome Technologies Inc.
- ACADIA Pharmaceuticals Inc.
- Medivation, Inc.
- Keryx Biopharmaceuticals, Inc.
- EPIX Pharmaceuticals, Inc.
- ProteoTech, Inc.
- Theratechnologies Inc.
- Phytopharm Plc
- SYGNIS Pharma AG
- Prana Biotechnology Limited
- Hanall Pharmaceutical Co., Ltd.
- SCOLR Pharma, Inc.
- Transition Therapeutics Inc.
- Neurim Pharmaceuticals (1991) Ltd.
- Samaritan Pharmaceuticals, Inc.
- Theravance, Inc.
- Suven Life Sciences Ltd.
- Galapagos NV
- MediPost Co., Ltd.
- Sucampo Pharmaceuticals, Inc.
- Proximagen Neuroscience plc.
- Newron Pharmaceuticals S.p.A.
- DiaMedica Inc.
- e-Therapeutics plc
- Mithridion, Inc.
- Teikoku Pharma USA, Inc.
- Xel Pharmaceuticals, Inc.
- Eisai Inc.
- Digna Biotech, S.L.
- Eusa Pharma (Europe) Ltd.
- TauRx Therapeutics Ltd
- Ceregene, Inc.
- Synosia Therapeutics AG
- CoMentis, Inc.
- AC Immune SA
- Debiopharm Group
- Humanetics Corporation
- Noscira, S.A.
- Sonexa Therapeutics, Inc.
- Immune Network Research Ltd.
- Bio-Link
- D-Pharm Ltd.
- TauTaTis, Inc.
- Probiodrug AG
- Snowdon Inc.
- Domain Therapeutics
- Abiogen Pharma S.p.A.
- Wellstat Therapeutics Corporation
- BIOALVO S.A.
- IMMD Inc.
- Hawthorn Pharmaceuticals, Inc.
- Neurimmune Therapeutics AG
- BioArctic Neuroscience AB
- Rottapharm SpA
- AmKor Pharma, Inc.
- QR Pharma, Inc.
- NeuroNascent, Inc.
- SeneXta Therapeutics SA
- Intellect Neurosciences, Inc.
- Transtech Pharma, Inc.
- Adeona Pharmaceuticals, Inc.
- Intra-Cellular Therapies, Inc.
- RemeGenix, Inc.
- AB Science
- Krenitsky Pharmaceuticals Inc.
- Lipopharma
- Medisyn Technologies, Inc.
- M's Science Corporation
- BrainCells Inc.
- Dainippon Pharmaceutical Co., Ltd.
- Varinel, Inc.
- RaQualia Pharma Inc.
- Naurex, Inc.
- Ampio Pharmaceuticals, Inc.
- Universities/Institutes Involved in Alzheimer's Disease Therapeutics Development
- Alzheimer's Disease Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Late Stage Drug Profiles - Companies
- Alzhemed - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bapineuzumab - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BCI-224 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Dimebon - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lecozotan - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- LY2062430 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Memryte - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- QS-21 Stimulon Adjuvant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- R113675 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SUN Y7017 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Late Stage Drug Profiles - Universities/Institutes
- Alpha-Tocopherol + Namenda - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Doxycycline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Doxycycline + Rifampicin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Estradiol + Medroxyprogesterone - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ginkgo Biloba - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Memantine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Raloxifene - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rifampin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Simvastatin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Sunphenon EGCg - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Thalidomide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valproate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Valproate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Vitamin E + Selenium - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Discontinued Products
- Alzheimer's Disease - Featured News
- Dec 02, 2010: QR Pharma Receives FDA Clearance To Conduct Clinical Trials With Alzheimer Drug
- Dec 02, 2010: QR Pharma Receives FDA Clearance To Conduct Clinical Trials With Bisnorcymserine In Treatment Of Alzheimer's Disease
- Nov 08, 2010: Prana Biotechnology Plans To Advance Alzheimer's Clinical Trial With PBT2
- Nov 05, 2010: Envivo Research Shows EVP-6124 Acts As Acetylcholine Co-Agonist
- Oct 27, 2010: Intellect Obtains Phase Ib Draft Report Of OXIGON For Treatment Of Alzheimer's Disease
- Oct 06, 2010: Adeona Completes 100% Enrollment In Pivotal Alzheimer’s Disease And Mild Cognitive Impairment Clinical Study
- Sep 24, 2010: Update Of Product Withdrawal/Product Recall Octopharm's Octagam 10% (octagam 100mg/ml)
- Sep 13, 2010: Anave Announces Publication Of Data On Anavex 2-73 For Alzheimer’s Disease In Journal of Psychopharmacology
- Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer’s Disease Model
- Aug 19, 2010: Curaxis Provides Update On Memryte For Treatment Of Alzheimer's Disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Alzheimer's Disease, 2010
- Products under Development for Alzheimer's Disease - Comparative Analysis, 2010
- Comparative Analysis by Late Stage Development, 2010
- Comparative Analysis by Mid Clinical Stage Development, 2010
- Comparative Analysis by Early Clinical Stage Development, 2010
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2010
- Bristol-Myers Squibb Company, 2010
- DURECT Corporation, 2010
- Johnson & Johnson, 2010
- Boehringer Ingelheim GmbH, 2010
- Abbott Laboratories, 2010
- NsGene A/S, 2010
- Sanofi-Aventis, 2010
- AstraZeneca PLC, 2010
- Eli Lilly and Company, 2010
- GlaxoSmithKline plc, 2010
- Antigenics, Inc., 2010
- Daiichi Sankyo Company, Ltd, 2010
- Merck & Co., Inc., 2010
- United Biomedical, Inc., 2010
- Dainippon Sumitomo Pharma Co., Ltd., 2010
- Myriad Genetics, Inc., 2010
- Takeda Pharmaceutical Company Limited, 2010
- ExonHit Therapeutics SA, 2010
- Plexxikon Inc., 2010
- Mochida Pharmaceutical Co., Ltd., 2010
- Avineuro Pharmaceuticals, Inc., 2010
- Senexis Limited, 2010
- Novartis AG, 2010
- EnVivo Pharmaceuticals, 2010
- DECODON GmbH, 2010
- Astellas Pharma Inc., 2010
- Cephalon, Inc., 2010
- Chiesi Farmaceutici SpA, 2010
- Daewoong Pharmaceutical Co., Ltd., 2010
- Elan Corporation, plc, 2010
- H Lundbeck A/S, 2010
- Octapharma AG, 2010
- Orion Corporation, 2010
- Pfizer Inc., 2010
- Sunesis Pharmaceuticals, Inc., 2010
- Teva Pharmaceutical Industries Limited, 2010
- Toyama Chemical Co. Ltd, 2010
- ENKAM Pharmaceuticals A/S, 2010
- Astex Therapeutics Limited, 2010
- Addex Pharmaceuticals, 2010
- Evotec Aktiengesellschaft, 2010
- Anavex Life Sciences Corp., 2010
- Amicus Therapeutics, Inc., 2010
- Genfit, 2010
- Idera Pharmaceuticals, Inc., 2010
- Ligand Pharmaceuticals Incorporated, 2010
- BELLUS Health Inc, 2010
- Medivir AB, 2010
- ReGenX Biosciences, LLC, 2010
- Neuren Pharmaceuticals Limited, 2010
- Neuro-Hitech, Inc., 2010
- Cortex Pharmaceuticals, Inc., 2010
- Critical Outcome Technologies Inc., 2010
- ACADIA Pharmaceuticals Inc., 2010
- Medivation, Inc., 2010
- Keryx Biopharmaceuticals, Inc., 2010
- EPIX Pharmaceuticals, Inc., 2010
- ProteoTech, Inc., 2010
- Theratechnologies Inc., 2010
- Phytopharm Plc, 2010
- SYGNIS Pharma AG, 2010
- Prana Biotechnology Limited, 2010
- Hanall Pharmaceutical Co., Ltd., 2010
- SCOLR Pharma, Inc., 2010
- Transition Therapeutics Inc., 2010
- Neurim Pharmaceuticals (1991) Ltd., 2010
- Samaritan Pharmaceuticals, Inc., 2010
- Theravance, Inc., 2010
- Suven Life Sciences Ltd., 2010
- Galapagos NV, 2010
- MediPost Co., Ltd., 2010
- Sucampo Pharmaceuticals, Inc., 2010
- Proximagen Neuroscience plc., 2010
- Newron Pharmaceuticals S.p.A., 2010
- DiaMedica Inc., 2010
- e-Therapeutics plc, 2010
- Mithridion, Inc., 2010
- Teikoku Pharma USA, Inc., 2010
- Xel Pharmaceuticals, Inc., 2010
- Eisai Inc., 2010
- Digna Biotech, S.L., 2010
- Eusa Pharma (Europe) Ltd., 2010
- TauRx Therapeutics Ltd, 2010
- Ceregene, Inc., 2010
- Synosia Therapeutics AG, 2010
- CoMentis, Inc., 2010
- AC Immune SA, 2010
- Debiopharm Group, 2010
- Humanetics Corporation, 2010
- Noscira, S.A., 2010
- Sonexa Therapeutics, Inc., 2010
- Immune Network Research Ltd., 2010
- Bio-Link, 2010
- D-Pharm Ltd., 2010
- TauTaTis, Inc., 2010
- Probiodrug AG, 2010
- Snowdon Inc., 2010
- Domain Therapeutics, 2010
- Abiogen Pharma S.p.A., 2010
- Wellstat Therapeutics Corporation, 2010
- BIOALVO S.A., 2010
- IMMD Inc., 2010
- Hawthorn Pharmaceuticals, Inc., 2010
- Neurimmune Therapeutics AG, 2010
- BioArctic Neuroscience AB, 2010
- Rottapharm SpA, 2010
- AmKor Pharma, Inc., 2010
- QR Pharma, Inc., 2010
- NeuroNascent, Inc., 2010
- SeneXta Therapeutics SA, 2010
- Intellect Neurosciences, Inc., 2010
- Transtech Pharma, Inc., 2010
- Adeona Pharmaceuticals, Inc., 2010
- Intra-Cellular Therapies, Inc., 2010
- RemeGenix, Inc., 2010
- AB Science, 2010
- Krenitsky Pharmaceuticals Inc., 2010
- Lipopharma, 2010
- Medisyn Technologies, Inc., 2010
- M's Science Corporation, 2010
- BrainCells Inc., 2010
- Dainippon Pharmaceutical Co., Ltd., 2010
- Varinel, Inc., 2010
- RaQualia Pharma Inc., 2010
- Naurex, Inc., 2010
- Ampio Pharmaceuticals, Inc., 2010
- Assessment by Monotherapy Products, 2010
- Assessment by Combination Products
- Assessment by Stage and Route of Administration, 2010
- Assessment by Molecule Type, 2010
- Discontinued Products
- List of Figures
- Number of Products under Development for Alzheimer's Disease, 2010
- Products under Development for Alzheimer's Disease - Comparative Analysis, 2010
- Products under Development by Companies, 2010
- Products under Investigation by Universities/Institutes, 2010
- Late Stage Products, 2010
- Mid Clinical Stage Products, 2010
- Early Clinical Stage Products, 2010
- Discovery and Pre-Clinical Stage Products, 2010
- Assessment by Monotherapy Products, 2010
- Assessment by Combination Products, 2010
- Assessment by Route of Administration, 2010
- Assessment by Stage and Route of Administration, 2010
- Assessment by Molecule Type, 2010
- Assessment by Stage and Molecule Type, 2010
AbstractAlzheimer's Disease - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Alzheimer's Disease Pipeline Review, Q4 2010”, provides an overview of the Alzheimer's Disease therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. “Alzheimer's Disease-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope- A snapshot of the global therapeutic scenario for Alzheimer's Disease.
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alzheimer's Disease pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Alzheimer's Disease therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
